注射液-话题@MedSci

#注射液#

122篇内容 | 2930人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1586582, encodeId=6031158658294, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=国家药监局发文：7种常见退烧药禁用，安乃近注射液、小儿解热栓……, objectType=article, longId=190561, objectId=fbeb19056195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbeb19056195, replyNumber=0, likeNumber=0, createdTime=2020-03-23, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbeb19056195, moduleTitle=国家药监局发文：7种常见退烧药禁用，安乃近注射液、小儿解热栓……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbeb19056195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586581, encodeId=1c401586581dc, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, objectType=article, longId=189508, objectId=d6db18950878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6db18950878, replyNumber=0, likeNumber=83, createdTime=2020-03-08, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6db18950878, moduleTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6db18950878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586580, encodeId=eac51586580aa, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, objectType=article, longId=185462, objectId=7bae18546288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bae18546288, replyNumber=0, likeNumber=59, createdTime=2020-01-01, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bae18546288, moduleTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bae18546288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586579, encodeId=b4ca15865e9e6, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, objectType=article, longId=185383, objectId=415318538314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415318538314, replyNumber=0, likeNumber=124, createdTime=2019-12-30, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415318538314, moduleTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415318538314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586578, encodeId=161e15865e828, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=警惕！临床用量极大的「脑苷肌肽注射液」「复方骨肽注射液」已被改说明书, objectType=article, longId=183581, objectId=a600183581f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a600183581f7, replyNumber=0, likeNumber=75, createdTime=2019-11-27, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a600183581f7, moduleTitle=警惕！临床用量极大的「脑苷肌肽注射液」「复方骨肽注射液」已被改说明书, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a600183581f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586577, encodeId=ce1b15865e764, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, objectType=article, longId=183553, objectId=65371835530b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65371835530b, replyNumber=0, likeNumber=38, createdTime=2019-11-26, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65371835530b, moduleTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65371835530b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586576, encodeId=388015865e6c8, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识, objectType=article, longId=183303, objectId=b423183303e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b423183303e4, replyNumber=0, likeNumber=31, createdTime=2019-11-21, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b423183303e4, moduleTitle=锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b423183303e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586575, encodeId=74c215865e54c, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=2019年ACR / ARP：Mallinckrodt公布Acthar凝胶（促肾上腺皮质激素注射液）治疗RA的全新数据, objectType=article, longId=182958, objectId=d98f1829587b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98f1829587b, replyNumber=0, likeNumber=70, createdTime=2019-11-15, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98f1829587b, moduleTitle=2019年ACR / ARP：Mallinckrodt公布Acthar凝胶（促肾上腺皮质激素注射液）治疗RA的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d98f1829587b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586574, encodeId=d2c915865e441, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=脊髓性肌萎缩症治疗药物诺西那生钠注射液在全国开启患者治疗, objectType=article, longId=180942, objectId=0f31180942c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f31180942c2, replyNumber=0, likeNumber=55, createdTime=2019-10-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f31180942c2, moduleTitle=脊髓性肌萎缩症治疗药物诺西那生钠注射液在全国开启患者治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f31180942c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586573, encodeId=1cb715865e3e7, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=Anesth Analg：氯胺酮注射液治疗慢性疼痛:随机对照试验的系统回顾和荟萃分析, objectType=article, longId=180268, objectId=9f3918026864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f3918026864, replyNumber=0, likeNumber=36, createdTime=2019-10-01, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f3918026864, moduleTitle=Anesth Analg：氯胺酮注射液治疗慢性疼痛:随机对照试验的系统回顾和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f3918026864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586572, encodeId=ada215865e2c3, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, objectType=article, longId=179251, objectId=fc171e9251bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc171e9251bb, replyNumber=0, likeNumber=62, createdTime=2019-09-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc171e9251bb, moduleTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc171e9251bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586571, encodeId=308e15865e17b, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批, objectType=article, longId=178813, objectId=48531e881371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48531e881371, replyNumber=0, likeNumber=80, createdTime=2019-09-06, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48531e881371, moduleTitle=重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48531e881371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586570, encodeId=ffb415865e073, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, objectType=article, longId=175621, objectId=98461e5621b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98461e5621b5, replyNumber=0, likeNumber=71, createdTime=2019-07-18, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98461e5621b5, moduleTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98461e5621b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586569, encodeId=79eb158656945, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=甘露醇注射液的28种配伍禁忌, objectType=article, longId=168514, objectId=bd8a168514e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd8a168514e6, replyNumber=0, likeNumber=76, createdTime=2019-06-17, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd8a168514e6, moduleTitle=甘露醇注射液的28种配伍禁忌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd8a168514e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586568, encodeId=6b051586568e7, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=Crit Care Med：血必净注射液治疗社区获得性肺炎重症患者的疗效, objectType=article, longId=168098, objectId=3f9b168098a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f9b168098a0, replyNumber=0, likeNumber=78, createdTime=2019-06-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f9b168098a0, moduleTitle=Crit Care Med：血必净注射液治疗社区获得性肺炎重症患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f9b168098a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586567, encodeId=960b158656e92, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=肾康制剂（肾康注射液、肾康栓）治疗慢性肾脏病合理应用专家共识, objectType=article, longId=167966, objectId=e82516e96644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82516e96644, replyNumber=0, likeNumber=33, createdTime=2019-06-11, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82516e96644, moduleTitle=肾康制剂（肾康注射液、肾康栓）治疗慢性肾脏病合理应用专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e82516e96644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586566, encodeId=b36b158656691, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=步长制药否认丹红注射液不良反应但岔路口的中成药企业向何处去？, objectType=article, longId=166688, objectId=e0881666887e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0881666887e, replyNumber=0, likeNumber=49, createdTime=2019-05-25, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0881666887e, moduleTitle=步长制药否认丹红注射液不良反应但岔路口的中成药企业向何处去？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0881666887e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586565, encodeId=718b1586565e1, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=因不良反应再遭质疑，中药注射液将何去何从？, objectType=article, longId=165837, objectId=c7ab16583ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ab16583ed7, replyNumber=0, likeNumber=55, createdTime=2019-05-12, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ab16583ed7, moduleTitle=因不良反应再遭质疑，中药注射液将何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ab16583ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586564, encodeId=2ca51586564d5, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=王志安的“开中药注射液缺德论”：哪部分合理？哪部分不合理？, objectType=article, longId=165583, objectId=556f1655835d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556f1655835d, replyNumber=0, likeNumber=53, createdTime=2019-05-09, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556f1655835d, moduleTitle=王志安的“开中药注射液缺德论”：哪部分合理？哪部分不合理？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556f1655835d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1586563, encodeId=8df9158656392, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, objectTitle=全球脊髓性肌萎缩症治疗药物诺西那生钠注射液正式在中国上市, objectType=article, longId=165177, objectId=71331651e715, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71331651e715, replyNumber=0, likeNumber=59, createdTime=2019-04-30, rootId=0, userName=shijzhiewnjhch, userId=c93417353045, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71331651e715, moduleTitle=全球脊髓性肌萎缩症治疗药物诺西那生钠注射液正式在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71331651e715)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

注射液

2020-05-29

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

国家药监局发文：7种常见退烧药禁用，安乃近注射液、小儿解热栓……

2020-03-23

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代

2020-03-08

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批

2020-01-01

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了

2019-12-30

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

警惕！临床用量极大的「脑苷肌肽注射液」「复方骨肽注射液」已被改说明书

2019-11-27

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作

2019-11-26

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识

2019-11-21

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

2019年ACR / ARP：Mallinckrodt公布Acthar凝胶（促肾上腺皮质激素注射液）治疗RA的全新数据

2019-11-15

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

脊髓性肌萎缩症治疗药物诺西那生钠注射液在全国开启患者治疗

2019-10-12

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

Anesth Analg：氯胺酮注射液治疗慢性疼痛:随机对照试验的系统回顾和荟萃分析

2019-10-01

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据

2019-09-12

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批

2019-09-06

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂

2019-07-18

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

甘露醇注射液的28种配伍禁忌

2019-06-17

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

Crit Care Med：血必净注射液治疗社区获得性肺炎重症患者的疗效

2019-06-12

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

肾康制剂（肾康注射液、肾康栓）治疗慢性肾脏病合理应用专家共识

2019-06-11

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

步长制药否认丹红注射液不良反应但岔路口的中成药企业向何处去？

2019-05-25

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

因不良反应再遭质疑，中药注射液将何去何从？

2019-05-12

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

王志安的“开中药注射液缺德论”：哪部分合理？哪部分不合理？

2019-05-09

shijzhiewnjhch (审核中...)

前往app查看评论内容

#注射液#

全球脊髓性肌萎缩症治疗药物诺西那生钠注射液正式在中国上市

2019-04-30

科室
- - 订阅+
  - 更多科室
工具
服务